[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100619251":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":29,"centralContacts":24,"locations":33,"responsibleParty":47,"collaborators":24,"id":49,"slug":50,"hasResults":51,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":24,"eligibilityCriteria":55,"healthyVolunteers":56,"sex":57,"minAge":58,"maxAge":59,"enrollmentInfo":60,"targetDuration":24,"studyType":63,"phases":64,"briefSummary":66,"conditions":67,"keywords":24,"overallStatus":69,"whyStopped":24,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":79},{"fullName":5,"class":6},"Radicle Science","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Placebo Clarity Control","PLACEBO_COMPARATOR","Clarity Product Placebo Control",[13],"Dietary Supplement: Clarity Product Placebo Control",{"label":15,"type":16,"description":15,"interventionNames":17},"RS Active Clarity Product","EXPERIMENTAL",[18],"Dietary Supplement: RS Clarity Active Product",[20,25],{"type":21,"name":11,"description":22,"armGroupLabels":23,"otherNames":24},"DIETARY_SUPPLEMENT","Participants will use their Clarity Product Placebo Control as directed for a period of 12 weeks.",[9],null,{"type":21,"name":26,"description":27,"armGroupLabels":28,"otherNames":24},"RS Clarity Active Product","Participants will use their RS Clarity Active Product as directed for a period of 12 weeks",[15],[30],{"name":31,"affiliation":5,"role":32},"Susan Hewlings","PRINCIPAL_INVESTIGATOR",[34],{"facility":35,"status":24,"city":36,"state":37,"zip":38,"country":39,"countryCode":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":24},"Radicle Science Inc.","Del Mar","California","92014","United States","US",{"type":42,"coordinates":43},"Point",[44,45],-117.26531,32.95949,{"lat":45,"lon":44},{"type":48,"investigatorFullName":24,"investigatorTitle":24,"investigatorAffiliation":24,"oldNameTitle":24,"oldOrganization":24},"SPONSOR","100619251","radicle-clarity-dsttm-a-study-assessing-the-impact-of-health-and-wellness-products-on-mental-clarity-and-related-health-outcomes-100619251",false,"NCT07342192","Radicle Clarity DSTTM: A Study Assessing the Impact of Health and Wellness Products on Mental Clarity and Related Health Outcomes","Radicle Clarity DSTTM: A Randomized, Double-Blind, Placebo-Controlled Direct-to-Consumer Study Assessing the Impact of Health and Wellness Products on Mental Clarity and Related Health Outcomes","Inclusion\n\nParticipants must meet all the following criteria:\n\n* Adults, 35-60 years of age (inclusive) at the time of electronic consent, inclusive of all ethnicities, races, and gender identities\n\n  * Assigned sex at birth will determine sex-specific recruitment and surveys (male vs female) employed, when needed\n* Resides in the United States\n* Has the opportunity for at least 30% improvement in their primary health outcome\n* Expresses a willingness to take a study product and not know the product identity(active or placebo) until the end of the study\n\nExclusion\n\nIndividuals who report any of the following during screening may be excluded from participation:\n\n* Report being pregnant, trying to become pregnant, or breastfeeding\n* Unable to provide a valid US shipping address and mobile phone number\n* Reports current enrollment in another clinical trial\n* Reports being a heavy drinker (defined as drinking 3 or more alcoholic beverages per day)\n* Unable to read and understand English at a 7th grade level\n* Reports a current and\u002For recent (up to 3 months ago) major illness and\u002For surgery that poses a known, significant safety risk.\n* Reports a diagnosis of cardiac dysfunction, liver or kidney disease that presents a known contraindication and\u002For a significant safety risk with any of the study product ingredients.\n\n  * NYHA Class III or IV congestive heart failure, atrial fibrillation, uncontrolled arrhythmias, cirrhosis, end-stage liver disease, stage 3b or 4 chronic kidney disease, or kidney failure\n* Reports taking medications that have a well-established moderate or severe interaction, posing a substantial safety risk with any of the study product ingredients.\n\n  * Anticoagulants, antihypertensives, anxiolytics, antidepressants, chemotherapy, immunotherapy, sedative hypnotics, seizure medications, medications that warn against grapefruit consumption, corticosteroids at doses greater than 5 mg per day, diabetic medications, oral anti-infectives (antibiotics, antifungals, antivirals) to treat an acute infection, antipsychotics, MAOIs, or thyroid products\n* Reports current use of the primary ingredient(s) and\u002For similar product(s) to the active study product(s) that may limit the effects of the study products and\u002For pose a safety risk\n* Lack of reliable daily access to the internet\n* Reports current use of prescription medication(s) for cognitive enhancement\n* Reports current regular cannabis use",true,"ALL","35 Years","60 Years",{"count":61,"type":62},990,"ESTIMATED","INTERVENTIONAL",[65],"NA","Radicle Clarity DSTTM: A randomized, double-blind, placebo-controlled direct-to-consumer study assessing the impact of health and wellness products on mental clarity and related health outcomes.",[68],"Cognitive Function","ACTIVE_NOT_RECRUITING","2026-08-18",{"date":72,"type":73},"2026-08-20","ACTUAL",{"date":75,"type":73},"2026-01-22",{"date":77,"type":62},"2027-01-21",{"name":5,"class":6},1]